Trends of COVID-19 pediatric admissions number during the first 24 weeks of COVID-19 vaccination in Rio de Janeiro, Brazil / Tendências do número de admissões pediátricas da COVID-19 durante as primeiras 24 semanas de vacinação da COVID-19 no Rio de Janeiro, Brasil
DOI:
https://doi.org/10.34119/bjhrv5n2-153Keywords:
COVID 19, paediatrics, infectious disease medicine.Abstract
Objective: To describe trends of COVID-19 pediatric admissions number during the first 24 weeks of COVID-19 vaccination. Design: A retrospective study was conducted in children (0-18 years), admitted in two pediatric hospitals of Rio de Janeiro city, between January 17 and July 3, 2021 with confirmed COVID-19 by reverse transcription polymerase chain reaction or serological tests. Trends of COVID-19 pediatric admissions number during the first 24 weeks of COVID-19 vaccination in Rio de Janeiro, Brazil and the pre-vaccine period were measured by linear regression. Participants: Children admitted in pediatric hospitals in Rio de Janeiro, city, Brazil Results: The number of total admitted patients (with all diseases) were 5340 during the pre-vaccine period, being 94 (1.8%) of them with confirmed COVID-19, and 4182 children admitted during the vaccine period, with 86 confirmed COVID-19 patients (2.1 %) (p=0.29). Media of cases admitted per/week were 2.02 in pre-vaccine period and 3.6 during the first 24 weeks of COVID vaccination (p=0.009). One death was reported in the pre-vaccine period and four in the vaccine period (p=0.14). Trends of increase in the number of admitted cases were verified both in the pre-vaccine period as in the vaccine period, being more expressive in the last one. Conclusion: There was trend of increase in number of children admitted with confirmed COVID-19 during the first 24 weeks of COVID-vaccination in Rio de Janeiro, city. Considering that few people were fully vaccinated, reducing of number of admitted children with confirmed COVID-19 was not verified.
References
Ramos AM, Vela-Pérez M, Ferrández MR, Kubik AB, Ivorra B. Modeling the impact of SARS-CoV-2 variants and vaccines on the spread of COVID-19. Commun Nonlinear Sci Numer Simul. 2021 Nov;102:105937. doi: 10.1016/j.cnsns.2021.105937. Epub 2021 Jun 24. PMID: 34188432; PMCID: PMC8223013.
Haug N, Geyrhofer L, Londei A, Dervic E, Desvars-Larrive A, Loreto V, Pinior B, Thurner S, Klimek P. Ranking the effectiveness of worldwide COVID-19 government interventions. Nat Hum Behav. 2020 Dec;4(12):1303-1312. doi: 10.1038/s41562-020-01009-0. Epub 2020 Nov 16. PMID: 33199859.
Mantovani A, Rinaldi E, Zusi C, Beatrice G, Saccomani MD, Dalbeni A. Coronavirus disease 2019 (COVID-19) in children and/or adolescents: a meta-analysis. Pediatr Res. 2021 Mar;89(4):733-737. doi: 10.1038/s41390-020-1015-2. Epub 2020 Jun 17. PMID: 32555539.
Kaushik A, Gupta S, Sood M, Sharma S, Verma S. A Systematic Review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 Infection. Pediatr Infect Dis J. 2020 Nov;39(11):e340-e346. doi: 10.1097/INF.0000000000002888. PMID: 32925547.
Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, Simmons R, Cottrell S, Roberts R, O'Doherty M, Brown K, Cameron C, Stockton D, McMenamin J, Ramsay M. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021 May 13;373:n1088. doi: 10.1136/bmj.n1088. PMID: 33985964; PMCID: PMC8116636.
Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, Pan K, Southern J, Swerdlow DL, Jodar L, Levy Y, Alroy-Preis S. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021 May 15;397(10287):1819-1829. doi: 10.1016/S0140-6736(21)00947-8. Epub 2021 May 5. Erratum in: Lancet. 2021 Jul 17;398(10296):212. PMID: 33964222; PMCID: PMC8099315.
Painel Rio COVID-19. Available at : https://experience.arcgis.com/experience/38efc69787a346959c931568bd9e2cc4 Accessed on September 03, 2021.
WHO Coronavirus (COVID-19) Dashboard. Available at: https://covid19.who.int/ Accessed on September 2, 2021.
Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021 Feb;21(2):e26-e35. doi: 10.1016/S1473-3099(20)30773-8. Epub 2020 Oct 27. PMID: 33125914; PMCID: PMC7837315.
Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, Wellington E, Stowe J, Gillson N, Atti A, Islam J, Karagiannis I, Munro K, Khawam J, Chand MA, Brown CS, Ramsay M, Lopez-Bernal J, Hopkins S; SIREN Study Group. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021 May 8;397(10286):1725-1735. doi: 10.1016/S0140-6736(21)00790-X. Epub 2021 Apr 23. PMID: 33901423; PMCID: PMC8064668.
